Effects on haemodynamics by selective endothelin ET(B) receptor and combined endothelin ET(A)/ET(B) receptor antagonism during endotoxin shock

European Journal of Pharmacology

Volumn 386, Issue 2-3, 1999, Pages 235-245

  Wanecek, Michael ^a   Oldner, Anders ^a   Sundin, Pierre ^a   Alving, Kjell ^b   Weitzberg, Eddie ^a   Rudehill, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

A 192621; Endothelin ET(A) receptor; Endothelin ET(B) receptor; Endothelin 1; Endotoxaemia; PD 155080; Septic shock

Indexed keywords

(2ALPHA,3BETA,4ALPHA) 4 (1,3 BENZODIOXOL 5 YL) 1 [2 (2,6 DIETHYLPHENYL)AMINO] 2 OXOETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; 3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; BACTERIUM LIPOPOLYSACCHARIDE; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; OXYGEN; UNCLASSIFIED DRUG;

ACID BASE BALANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; DISEASE COURSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FATALITY; FEMALE; HEART AFTERLOAD; HEART PERFORMANCE; INOTROPISM; MALE; NONHUMAN; OXYGEN TRANSPORT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEPTIC SHOCK;

ANIMALS; DIOXOLES; ENDOTHELIN-1; ENDOTOXINS; FEMALE; HEMODYNAMIC PROCESSES; HEMOGLOBINS; HYDROGEN-ION CONCENTRATION; MALE; PULMONARY CIRCULATION; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; SHOCK, SEPTIC; SWINE;

EID: 0033398961     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00774-8     Document Type: Article

References (52)

1. Bassenge E. Endothelial function in different organs. Prog. Cardiovasc. Dis. 39:1996;209-228.
2. Battistini B., Forget A.-M., Laight D. Potential roles for endothelins in systemic inflammatory response syndrome with a particular relation to cytokines. Shock. 5:1996;167-183.
3. Beyer M.E., Slesak G., Hoffmeister H.M. In vivo hemodynamic and inotropic effects of the endothelinB agonist IRL 1620. J. Cardiovasc. Pharmacol. 26(Suppl. 3):1995;S190-S192.
4. Bigatello L., Zapol M. New approaches to acute lung injury. Britt. J. Anaesth. 77:1996;99-109.
5. Cannan C.R., Burnett J.C. Jr., Lerman A. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation. 93:1996;646-651.
6. Caramelo C., Lopez Farre A., Riesco A., Casado S. Role of endothelin-1 in the activation of polymorphonuclear leukocytes. Kidney Int. 52:1997;56-59.
7. Curzen N.P., Mitchell J.A., Jourdan K.B., Griffiths M.J, Evans T.W. Endothelin-1-induced contraction of pulmonary arteries from endotoxemic rats is attenuated by the endothelin-A receptor antagonist, BQ123. Crit. Care Clin. 24:1996;2007-2013.
8. Curzen N.P., Kaddoura S., Griffiths M.J., Evans T.W. Endothelin-1 in rat endotoxemia: mRNA expression and vasoreactivity in pulmonary and systemic circulations. Am. J. Physiol. 272:1997;H2353-H2360.
9. De Nucci G., Thomas R., d'0rleans-Juste P. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyklin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. U.S.A. 85:1988;9797-9800.
10. Druml W., Steltzer H., Waldhausl W., Lenz K., Hammerle H., Vierhapper A., Gasic S., Wagner O. Endothelin-1 in adult respiratory distress syndrome. Am. Rev. Respir. Dis. 65(148):1993;1169-1173.
11. Dupuis J., Goresky C.A., Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J. Appl. Physiol. 81:1996;1510-1515.
12. Ehrenreich H., Schilling L. New developments in the understanding of cerebral vasoregulation and vasospasm: the endothelin-nitric oxide network. Cleveland Clin. Q. 62:1995;105-116.
13. Elshourbagy N.A., Adamou J.E., Gagnon A.W., Wu H.L., Pullen M., Nambi P. Molecular characterization of a novel human endothelin receptor splice variant. J. Biol. Chem. 271:1996;25300-25307.
14. Filippelli A., Falciani M., Palla A., D'Amico M., Vacca C., Rossi F. Distribution of endothelin-1-receptor subtypes in rat portal vein. J. Cardiovasc. Pharmacol. 27:1996;113-118.
15. B receptor subtypes for antagonism of endothelin-1-induced contraction in human bronchi. Br. J. Pharmacol. 117:1996;995-999.
16. Goldie R.G., Knott P.G., Carr M.J., Hay D.W., Henry P.J. The endothelins in the pulmonary system. Pulm. Pharmacol. 9:1996;69-93.
17. Helset E., Ytrehus K., Tveita T., Kjëve J., Jörgensen L. ET-1 causes accumulation of leukocytes in the pulmonary circulation. Circ. Shock. 44:1994;201-209.
18. Hemsen A. Biochemical and functional characterization of endothelin peptides with special references to vascular effects. Acta. Physiol. Scand. 142(Suppl. 602):1991;5-61.
19. Herbertson M.J., Werner H.A., Walley K.R. Nitric oxide synthase inhibition partially prevents decreased LV contractility during endotoxemia. Am. J. Physiol. 270:1996;H1979-H1984.
20. Hohlfeld T., Klemm P., Thiemermann C., Warner T.D., Schror K. The contribution of tumour necrosis factor - alpha and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin. Br. J. Pharmacol. 116:1995;3309-3315.
21. A receptor antagonist, BMS-182874, reduces acute hypoxic pulmonary hypertension in pigs in vivo. Cardiovasc. Res. 37:1998;765-771.
22. Ishikawa T., Yanagisawa M., Kimura S., Goto K., Masaki T. Positive inotropic actions of novel vasoconstrictor peptide endothelin on guinea pig atria. Am. J. Physiol. 255:1988;H970-H973.
23. Kiely D.G., Cargill R.I., Struthers A.D., Lipworth B.J. Cardiopulmonary effects of endothelin-1 in man. Cardiovasc. Res. 33:1997;378-386.
24. Kiowski W., Sütsch G., Hunziker P., Müller P., Kim J., Oechslin E., Schmitt R., Jones R., Bertel O. Evidence of ET-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
25. Kumar A., Thota V., Dee L., Olson J., Uretz E., Parrillo J.E. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J. Exp. Med. 183:1996;949-958.
26. Leeper-Woodford S., Carey P., Byrne K., Fisher J., Blocher C., Sugerman H., Fowler A. III Ibuprofen attenuates plasma tumor necrosis factor activity during sepsis-induced acute lung injury. J. Appl. Physiol. 71:1991;915-923.
27. B receptors in venous and arterial smooth muscle. Eur. J. Pharmacol. 287:1995;279-285.
28. MacLean M.R., Mackenzie J.F., Docherty C.C. Heterogeneity of endothelin-B receptors in rabbit pulmonary resistance arteries. J. Cardiovasc. Pharmacol. 31(Suppl. 1):1998;S115-S118.
29. Mebazaa A., Mayoux E., Maeda K., Martin L.D., Lakatta E.G., Robotham J.L., Shah A.M. Paracrine effects of endocardial endothelial cells on myocyte contraction mediated via endothelin. Am. J. Physiol. 265:1993;H1841-H1846.
30. Miasiro N., Karaki H., Paiva A.C. Distinct endothelin-B receptors mediate the effects of Sarafotoxin S6c and IRL1620 in the ileum. J. Cardiovasc. Pharmacol. 31(Suppl. 1):1998;175-178.
31. B receptors in rat isolated small mesenteric arteries. Br. J. Pharmacol. 120:1997;1376-1382.
32. B receptors. J. Biochem. (Tokyo). 121:1997;440-447.
33. Parillo J., Parker M., Natanson C., Suffredini A., Danner R., Cunnion R., Ognibene F. Septic shock in humans. Ann. Intern. Med. 113:1990;227-242.
34. Pernow J., Wang Q.D. Endothelin in myocardial ischaemia and reperfusion. Cardiovasc. Res. 33:1997;518-526.
35. Peyton M.D., Hinshaw L.B., Greenfield L.J., Elkins R.C. The effects of coronary vasodilatation on cardiac performance during endotoxin shock. Surg. Gynecol. Obstet. 143:1976;533-538.
36. Piero C. Influence of endothelium on cultured vascular smooth muscle cell proliferation. Hypertension. 25:1995;748-751.
37. Pittet J., Morel D., Hemsen A., Gunning K., Lacroix J.-S., Suter P., Lundberg J.M. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann. Surg. 213:1991;261-264.
38. Reeder L.B., Ferguson M.K. Endothelin-1 synthesis and receptor-mediated activity in porcine lymph vessels. J. Surg. Res. 63:1996;215-219.
39. A receptors. Eur. J. Pharmacol. 338:1997;199-203.
40. Shindo T., Kurihara H., Kurihara Y., Morita H., Yazaki Y. Upregulation of endothelin-1 and adrenomedullin gene expression in the mouse endotoxin shock model. J. Cardiovasc. Pharmacol. 31(Suppl. 1):1998;S541-S544.
41. Stewart D., Levy R., Cernacek P., Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker of mediator of disease? Ann. Intern Med. 114:1991;464-469.
42. B receptors. Acta. Chim. Hung. 36:1997;340-342.
43. Wanecek M., Oldner A., Rudehill A., Sollevi A., Alving K., Weitzberg E. Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan. Shock. 7:1997;364-370.
44. Wanecek M., Rudehill A., Hemsen A., Lundberg J.M., Weitzberg E. The endothelin receptor antagonist, bosentan, in combination with the cyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock. Crit. Care. Clin. 25:1997;848-857.
45. Wanecek M., Oldner A., Rudehill A., Sollevi A., Alving K., Weitzberg E. Endothelin-A-receptor antagonism attenuates pulmonary hypertension in porcine endotoxin shock. Eur. Respir. J. 13:1999;145-151.
46. A receptor-mediated coronary vasoconstriction after coronary thrombosis and thrombolysis in pigs. J. Cardiovasc. Pharmacol. 26:1995;770-776.
47. Weitzberg E., Lundberg J.M., Rudehill A. Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ. Shock. 33:1991;222-227.
48. Weitzberg E., Rudehill A., Lundberg J.M. Nitric oxide inhalation attenuates pulmonary hypertension and improves gas exchange in endotoxine shock. Eur. J. Pharm. Sci. 233:1993;85-94.
49. Weitzberg E., Lundberg J.M., Rudehill A. Inhibitory effects of diclofenac on the endotoxin shock response in relation to endothelin turnover in the pig. Acta Anaesthesiol. Scand. 39:1995;50-59.
50. Weitzberg E., Hemsen A., Rudehill A., Modin A., Wanecek M., Lundberg J.M. Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock. Br. J. Pharm. 118:1996;617-626.
51. Vincent J.L. Cardiovascular alterations in septic shock. J. Antimicriob. Chemother. 41:1998;9-15.
52. Vlessis A., Goldman R., Trunkey D. New concepts in the pathophysiology of oxygen metabolism during sepsis. Br. J. Surg. 82:1995;870-876.